Introducing a point mutation identified in a patient with pituitary resistance to thyroid hormone (Arg 338 to Trp) into other mutant thyroid hormone receptors weakens their dominant negative activities

Journal of Endocrinology

Volumn 151, Issue 2, 1996, Pages 293-300

  Ando, S ^a   Nakamura, H ^a   Sasaki, S ^b   Nishiyama, K ^a   Kitahara, A ^a   Nagasawa, S ^a   Mikami, T ^a   Natsume, H ^a   Genma, R ^a   Yoshimi, T ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; THYROID HORMONE; THYROID HORMONE RECEPTOR;

ARTICLE; CONTROLLED STUDY; HORMONE RESISTANCE; HUMAN; HUMAN CELL; MOLECULAR GENETICS; MUTATION; PRIORITY JOURNAL;

EID: 10544252278     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1510293     Document Type: Article

References (28)

1. Adams M, Matthews C, Collingwood TN, Tone Y, Beck-Peccoz P & Chatterjee KK 1994 Generic analysis of 29 kindreds with generalized and pituitay resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor β gene. Journal of Clinical Investigation 94 506-515.
2. Akiyama K, Yokota K, Kagawa S, Shimbara N, DeMartino GN, Slaughter CA, Noda C & Tanaka K 1995 cDNA cloning of a new putative ATPase subunit p45 of the human 26S proteasome, a homolog of yeast transcriptional factor Sug1p. FEBS Letters 363 151-156.
3. Baur E, Zechel C, Heery D, Heine MJS, Garnier JM, Vivat V, Douarin BL, Gronemeyer H, Chambon P & Lossen R 1996 Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO Journal 15 110-124.
4. Beck-Peccoz P, Roncoroni R, Narnotti S, Medri G, Marcocci C, Brabant G, Forloni F, Pinchera A & Faglia G 1990 Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. Journal of Clinical Endocrinology and Metabolism 71 19-25.
5. Beck-Peccoz P, Chatterjee VKK, Chin WW, DeGroot LJ, Jameson JL, Nakamura H, Refetoff S, Usala SJ & Weintroub BD 1993 Nomenclature of thyroid hormone receptor β-gene mutations in resistance to thyroid hormone: consensus statement from the First Workshop on Thyroid Hormone Resistance, 10-11 July 1993, Cambridge, UK. Journal of Clinical Endocrinology and Metabolism 78 990-993.
6. Cavaillés V, Dauvois S, Danielian PS & Parker MG 1994 Interaction of proteins with transcriptionally active estrogen receptors. Proceedings of the National Academy of Sciences of the USA 91 10009-10013.
7. Chen JD & Evance RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377 454-457.
8. Collingwood TN, Adams M, Tone Y & Chatterjee VKK 1994 Spectrum of transciptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone β-receptors in thyroid hormone resistance syndrome. Molecular Endocrinology 8 1262-1277.
9. Flynn TR, Anthony NH, Cohen O, Menke JB, Usala ST, Tollin S, Hegarty NK & Wondisford FE 1994 A novel C-terminal domain in the thyroid hormone receptor selectively mediates thyroid hormone inhibition. Journal of Biological Chemistry 269 32713-32716.
10. Geffner ME, Su F, Ross NS, Hershman JM, Dop CV, Menke JB, Hao E, Stanzak RK, Eaton T, Samuels HH & Usala SJ 1993 An arginine to histidine mutation in codon 311 of the C-erbAβ gene results in a mutant thyroid hormone receptor that does not mediate a dominant negative phenotype. Journal of Clinical Investigation 91 538-546.
11. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C & Brown M 1994 Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264 1455-1458.
12. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK & Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 397-404.
13. Kitajima K, Nagaya T & Jameson L 1995 Dominant negative and DNA-binding properties of mutant thyroid hormone receptors that are defective in homodimerization but not heterodimerization. Thyroid 5 343-353.
14. Kurokawa R, Söderström M, Hörlein A, Halachmi S, Brown M, Rosenfeld MG & Glass CK 1995 Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377 451-454.
15. Lee JW, Ryan F, Swaffield JC, Johnson SA & Moor DD 1995 Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374 91-94.
16. Mixon AJ, Renault JC, Ransom S, Bodenner DL & Weintroub BD 1993 Identification of a novel mutation in the gene encoding the β-triiodothyronine receptor in a patient with apparent selective pituitary resistance to thyroid hormone. Clinical Endocrinology 38 227-234.
17. Miyoshi Y, Nakamura H, Sasaki S, Tagami T, Misaki T, Konishi J & Nakao K 1995 Two consecutive nucleotide substitutions resulting in the T3 receptor β gene resulting in an 11-amino acid truncation in a patient with generalized resistance to thyroid hormone. Molecular and Cellular Endocrinology 114 9-17.
18. Nakamura H, Miyoshi Y, Nishiyama K, Komatsu K & Nakao K 1995 Studies of the functions of different mutant T3 receptors with truncation of the extreme C-terminal activation domain. Thyroid 5 S-136 (Abstract).
19. Neumann JR, Morency CA & Russian KO 1987 A novel rapid assay for chloramphenicol acetyltransferase gene expression. Biotechniques 5 444-447.
20. Onate SA, Tsai SY, Tsai MJ & O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor. Science 270 1354-1358.
21. Refetoff S 1991 Thyroid hormone resistance syndrome. In Werner and Ingbar's The Thyroid, edn 6, pp 1280-1294. Eds LE Braverman & RD Utiger. Philadelphia: Lippincott.
22. Sakurai A, Takeda K, Ain K, Ceccarelli P, Nakai A, Seino S, Bell GI, Refetoff S & DeGroot LJ 1989 Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor β. Proceedings of the National Academy of Sciences of the USA 86 8977-8981.
23. Samuels HH, Stanly F & Casanova J 1979 Depletion of L-3,5,3′-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology 105 80-85.
24. Sasaki S, Nakamura H, Tagami T, Miyoshi Y, Tanaka, K & Imura H 1992 A point mutation of the T3 receptor β1 gene in a kindred of generalized resistance to thyroid hormone. Molecular and Cellular Endocrinology 84 159-166.
25. Sasaki S, Nakamura H, Tagami T, Miyoshi Y, Nogimori T, Mitsuma T & Imura H 1993 Pituitary resistance to thyroid hormone associated with a base mutation in the hormone-binding domain of the human 3,5,3′-L-triiodothyronine receptor-β. Journal of Clinical Endocrinology and Metabolism 76 1254-1258.
26. Sasaki S, Nakamura H, Tagami T, Miyoshi Y & Nakao K 1995 Functional properties of a mutant T3 receptor β (R338W) identified in a subject with pituitary resistance to thyroid hormone. Molecular and Cellular Endocrinology 113 109-117.
27. Umesono K, Murakami KK, Thompson CC & Evans RM 1991 Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65 1255-1266.
28. Yen PM, Sugawara A, Refetoff S & Chin WW 1992 New insights on the mechanism(s) of the dominant negative effect of mutant thyroid hormone receptor in generalized resistance to thyroid hormone. Journal of Clinical Investigation 90 1825-1831.